Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)

January 14, 2025 4:59 AM EST Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $1,185.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login